Novacyt agrees to acquire Southern Cross Diagnostics
23rd Feb 2026 12:29
(Sharecast News) - Novacyt announced on Monday that it has conditionally agreed to acquire Southern Cross Diagnostics for an initial cash consideration of AUD 8.5m (£4.45m), as the molecular diagnostics group looked to expand its footprint in the fast-growing Australian market and accelerate its path to profitability.
Read moreNovacyt flags improved second-half performance
22nd Oct 2025 13:29
(Sharecast News) - Novacyt said on Wednesday that it expects improved second-half performance in 2025, as it outlined a new growth strategy focused on accelerating product development, achieving sustained double-digit revenue growth, and returning to EBITDA profitability.
Read moreNovacyt subsidiary fined for HSE breach at 'historical operation'
12th Sep 2025 10:27
(Sharecast News) - Novacyt said on Friday that its Lab 21 Healthcare subsidiary has been fined £52,000 following the conclusion of a Health and Safety Executive prosecution relating to historical operations at its former Axminster site.
Read moreNovacyt flags strong full-year revenue growth
30th Jan 2025 12:11
(Sharecast News) - Novacyt reported strong revenue growth for 2024 in an update on Thursday, with unaudited statutory revenue reaching about £19.6m, an 85% increase from the prior year's £10.6m.
Read moreNovacyt recovers £12.2m in VAT after settling DHSC dispute
22nd Aug 2024 12:29
(Sharecast News) - Molecular diagnostics company Novacyt announced the successful recovery of £12.2m in VAT from HM Revenue and Customs (HMRC) on Thursday.
Read moreNovacyt settles High Court dispute with DHSC
11th Jun 2024 08:05
(Sharecast News) - Biotechnology group Novacyt and the UK's Department of Health and Social Care have reached a commercial settlement of all claims and counterclaims in High Court proceedings.
Read moreNovacyt gearing up for hearing in DHSC litigation
19th Apr 2024 11:02
(Sharecast News) - Molecular diagnostics specialist Novacyt updated the market on legal proceedings between itself and its subsidiary Primer Design against the Department of Health and Social Care (DHSC) on Friday.
Read moreNovacyt confirms end of Yourgene Taiwan disposal discussions
6th Feb 2024 12:48
(Sharecast News) - Novacyt announced on Tuesday that it had received formal notification from INEX Innovate terminating discussions around the acquisition of Yourgene Health Taiwan.
Read moreNovacyt taps Steve Gibson for CFO
2nd Jan 2024 08:12
(Sharecast News) - Biotechnology group Novacyt has appointed Steve Gibson to the role of chief financial officer with immediate effect.
Read moreNovacyt facing delays in disposal of Yourgene Taiwan
21st Dec 2023 15:49
(Sharecast News) - Molecular diagnostics company Novacyt updated the market on the conditional disposal of its laboratory in Taiwan, which it acquired as part of its purchase of Yourgene Health on 8 September.
Read moreNovacyt to buy Yourgene Health in £16.7m deal
3rd Jul 2023 09:07
(Sharecast News) - Yourgene Health surged on Monday after it agreed to be bought by Novacyt in a £16.7m deal.
Read moreUK regulator approves Novacyt Covid-19 test
6th Dec 2022 12:29
(Sharecast News) - Shares in clinical diagnostics specialist Novacyt sparked on Tuesday, after the UK regulator approved its latest Covid-19 test.
Read moreNovacyt's exsig receives UK approval
15th Jul 2022 08:43
(Sharecast News) - Clinical diagnostics group Novacyt's exsig Covid-19 Direct Real-Time PCR test has received approval from the UK's Health Security Agency.
Read moreNovacyt gets another Covid-19 test approved in the UK
17th Feb 2022 15:38
(Sharecast News) - Clinical diagnostics company Novacyt announced on Thursday that its 'PROmate' Covid-19 2G Real-Time PCR test had been approved in the UK, under the UK Health Security Agency's coronavirus test device approvals (CTDA) regulations.
Read moreNovacyt gets UK approval for 'genesig' Covid-19 test
26th Nov 2021 08:02
(Sharecast News) - Clinical diagnostics specialist Novacyt announced on Friday thatots 'genesig' Covid-19 real-time PCR test has been approved in the UK.
Read more